Immune checkpoint inhibitors are a type of anti-cancer drug that work by releasing the immune system’s brakes, which allows it to fight cancer cells like it would fight a bacterial invader. Now researchers are asking a different question: could the same approach — carefully adapted — help protect the brain in diseases like Parkinson’s and Alzheimer’s?
The answer is complicated. Because those same drugs, when given at cancer doses, can sometimes cause Parkinson’s-like symptoms rather than prevent them. This is what we know so far.
What Are Immune Checkpoint Inhibitors?
Your immune system is powerful. Left unchecked, it can attack healthy tissue as well as disease. To prevent this, the body has a series of built-in brakes — molecular signals that tell immune cells to stand down.
One of the most important is the PD-1/PD-L1 pathway. PD-1 is a receptor on T cells — white blood cells that patrol the body for threats. When PD-1 binds to its partner molecule, PD-L1, it puts the brakes on T cell activity. This protects healthy tissue from immune attack.
Cancer cells exploit this. They switch on PD-L1 to hide from the immune system — effectively telling T cells “nothing to see here.” Immune checkpoint inhibitors are drugs that block this signal, pulling the brakes off and allowing the immune system to recognise and attack the tumour.
Drugs like pembrolizumab and nivolumab work this way. They have dramatically improved outcomes in melanoma, lung cancer, and many other cancers. They are now a standard part of oncology care.
What Does This Have to Do with Parkinson’s?
In Parkinson’s disease, the immune system is not just a bystander. T cells infiltrate the substantia nigra — the brain region that degenerates in Parkinson’s. Microglia, the brain’s resident immune cells, become chronically activated. Neuroinflammation accelerates the loss of dopamine-producing neurons.
Recent research suggests that the PD-1/PD-L1 checkpoint is directly involved in this process.
A 2025 study by Zhang and colleagues measured PD-1 on T cells from 16 Parkinson’s patients and 16 healthy controls. PD-1 was significantly higher on several T cell types in the Parkinson’s group. Higher PD-1 expression correlated with sleep disturbance scores — suggesting this is not just a laboratory finding but something connected to real symptoms.
A 2024 paper in iScience (Chen et al.) found something equally striking. In Parkinson’s mouse and cell models, tiny particles released by affected neurons — called small extracellular vesicles — suppressed T cell activity. They did this by raising PD-L1 levels on the T cells themselves. When researchers blocked PD-L1, the T cell suppression reversed.
Put these findings together and a picture emerges. In Parkinson’s disease, the immune system’s brakes may be being applied too hard — dampening the immune response that might otherwise help clear toxic protein aggregates from the brain.
Why Does That Matter?
In a healthy brain, the immune system helps maintain balance. Specialised immune cells — including regulatory T cells and monocyte-derived macrophages — support the brain’s own housekeeping, helping clear debris and resolve local inflammation.
In Parkinson’s, and more broadly in ageing, this support breaks down. Peripheral immune cells become exhausted. The brain’s own inflammatory response becomes chronic and self-reinforcing, with no effective counterbalance from the outside.
One hypothesis is that restoring peripheral immune function — nudging exhausted T cells back into action, enabling monocyte-derived macrophages to reach the brain — could reduce neuroinflammation and slow neurodegeneration.
This is where the PD-1/PD-L1 pathway comes back in. If the brakes are being applied too hard, releasing them — carefully, transiently — might help restore the balance.
The Alzheimer’s Clinical Trial
The most advanced clinical evidence for this approach comes not from Parkinson’s disease but from Alzheimer’s — and it is relevant because the underlying immune mechanisms overlap significantly.
A 2025 first-in-human phase 1b trial (Croese et al., Nature Medicine) tested a new drug called IBC-Ab002 in 40 patients with early Alzheimer’s disease. IBC-Ab002 is an anti-PD-L1 antibody — it blocks PD-L1, releasing the immune checkpoint — but it has been specifically engineered to be short-lived. It clears from the body quickly, delivering a brief pulse of immune activation rather than sustained blockade.
This design is deliberate and important. Preclinical studies in mouse models had shown that transient PD-L1 blockade triggered monocyte-derived macrophages and regulatory T cells to home in on the brain, reducing neuroinflammation and slowing disease progression. But the effect required pulsatile treatment — a single dose set off a cascade that persisted long after the drug had cleared. Continuous blockade did not work in the same way.
The phase 1b trial was primarily a safety study. Forty patients received four infusions, twelve weeks apart, across five dose groups ranging from 1 to 30 mg per kilogram. The primary finding was reassuring: IBC-Ab002 was well tolerated at all doses. There were no treatment-related serious adverse events and no signs of amyloid-related imaging abnormalities — a safety concern that has complicated other Alzheimer’s drug trials.
Exploratory analyses of cerebrospinal fluid biomarkers — proteins that reflect neuronal damage — showed directional improvement at the highest dose tested, though the trial was too small to reach statistical significance.
This is an early signal, not proof of efficacy. But the safety profile opens the door to larger trials. And the mechanism — restoring peripheral immune support to a degenerating brain — is directly relevant to Parkinson’s disease.
The Paradox: The Same Drugs Can Cause Parkinsonism
Here is where the story becomes genuinely counterintuitive.
While researchers are exploring whether carefully engineered checkpoint blockade might protect the brain, standard cancer checkpoint inhibitors — given at oncological doses, continuously, systemically — can cause Parkinson’s-like symptoms as a rare side effect.
A 2024 case report in Annals of Movement Disorders (Silva et al.) describes a patient with T-cell lymphoma who developed a subacute Parkinsonian syndrome just two weeks after starting pembrolizumab. She developed fever and motor symptoms — stiffness, slowness, difficulty moving — that resolved after stopping the drug and treating with methylprednisolone (a steroid). When pembrolizumab was restarted, the symptoms returned.
Only a handful of similar cases have been reported in the literature. But the pattern is consistent. Checkpoint inhibitors, by releasing the immune brakes globally and persistently, can trigger autoimmune reactions that target dopaminergic neurons — the very cells that die in Parkinson’s disease.
This seems contradictory. How can the same pathway, when targeted, both protect and harm dopaminergic neurons?
Why the Paradox Makes Sense
The answer lies in how the pathway is engaged — not whether it is engaged.
In Parkinson’s disease, the problem is thought to be immune exhaustion. The peripheral immune system becomes too suppressed to support the brain’s clearance mechanisms. Local neuroinflammation continues unchecked because there is insufficient protective immune input from outside. The brakes are being applied too hard, in the wrong place.
Standard cancer checkpoint inhibitors remove those brakes globally, persistently, and at high doses. They do not distinguish between the protective immune signalling the brain needs and the damaging autoimmune responses it does not. In susceptible individuals, the result can be an inflammatory attack on dopaminergic neurons — the same cells that Parkinson’s disease destroys through a different mechanism.
IBC-Ab002, the drug in the Alzheimer’s trial, is designed to avoid this. Its short half-life means it is cleared quickly. Its Fc region has been modified to reduce interaction with immune cells in ways that could cause harm. And it is given intermittently — spacing doses far enough apart to allow the immune system to reset between each pulse.
The therapeutic window, if it exists, is narrow. Timing, dose, and duration all appear to matter enormously. The engineering required to get this right is substantial.
What This Means for Parkinson’s Disease
The PD-1/PD-L1 pathway is not yet a proven treatment for Parkinson’s disease. The clinical evidence is at an early stage and comes primarily from Alzheimer’s disease research. The direct Parkinson’s data — the Zhang and Chen studies — are mechanistic, not clinical.
But the biological case is coherent. The immune system is meaningfully involved in Parkinson’s pathology. The PD-1/PD-L1 axis appears to be dysregulated in Parkinson’s patients. Preclinical models suggest that transient, targeted restoration of immune function can reduce neuroinflammation and slow disease progression. And the first human trial of a precision-engineered checkpoint inhibitor in a related neurodegenerative disease has returned an encouraging safety signal.
The next few years will be watched closely. If the Alzheimer’s programme advances to a phase 2 efficacy trial and delivers positive results, a Parkinson’s-specific programme is a natural next step. Several research groups are already working in this direction.
For anyone living with Parkinson’s disease, the most immediately practical point from all of this is about the cancer drugs, not the experimental ones. If you or a family member is being treated with a checkpoint inhibitor for cancer — pembrolizumab, nivolumab, atezolizumab, or similar — and you notice new or worsening Parkinsonian symptoms, raise it with both your oncologist and your neurologist. Drug-induced neurological side effects from checkpoint inhibitors are rare, but they are real, and they are important to identify early.
The Bigger Picture
This area of research illustrates something important about where neurodegenerative disease science is heading. For decades, the focus was almost entirely on the brain itself — the neurons, the proteins that misfold within them, the pathological cascades that follow. The immune system was background noise.
That has changed. The immune system is now understood to be a central player in how neurodegenerative diseases begin, progress, and might be slowed. The PD-1/PD-L1 story is one of the most striking examples. The same pathway that cancer medicine learned to exploit for tumour killing may, in a different form and at a different dose, hold part of the answer to protecting the brain.
Getting that right will require precision. The brain is not a tumour. But the question being asked is now a serious one, and the tools to answer it are improving rapidly.
Sources
- Silva, Lénia, et al. “Subacute parkinsonism induced by immune checkpoint inhibitors.” Annals of Movement Disorders7.3 (2024): 224-226.
- Yoon, Jiyoung, et al. “Potential beneficial effects of PD-1/PD-L1 blockade in Alzheimer’s disease: A systematic review and meta-analysis of preclinical and clinical studies.” Molecular Psychiatry 31.2 (2026): 1156-1166.
- Croese, Tommaso, et al. “Immunotherapy with a short-lived anti-PD-L1 antibody in Alzheimer’s disease: a phase 1b, randomized, double-blind trial.” Nature Medicine (2026): 1-8.
- Zhang, Zhi-Ling, et al. “Upregulation of PD-1 on Peripheral T cells Subsets is Associated with Parkinson’s Disease.” Molecular Neurobiology 62.10 (2025): 13500-13512.
- Chen, Zhichun, et al. “Neuronal-enriched small extracellular vesicles trigger a PD-L1-mediated broad suppression of T cells in Parkinson’s disease.” Iscience 27.7 (2024).
- Moadab, Ali, et al. “Unmasking a Paradox: Roles of the PD-1/PD-L1 Axis in Alzheimer’s Disease-Associated Neuroinflammation.” Journal of Neuroimmune Pharmacology20.1 (2025): 46.
This post is for educational purposes and reflects current research evidence. It is not a substitute for advice from your own medical team. If you have concerns about any medication, speak to your doctor. Our team uses AI to be faster, but the facts are checked by our expert scientists.